144 related articles for article (PubMed ID: 19888861)
1. Vascular endothelial growth factor expression in invasive papillary thyroid carcinoma.
de Araujo-Filho VJ; Alves VA; de Castro IV; Lourenço SV; Cernea CR; Brandão LG; Ferraz AR
Thyroid; 2009 Nov; 19(11):1233-7. PubMed ID: 19888861
[TBL] [Abstract][Full Text] [Related]
2. The expression of vascular endothelial growth factor and the type 1 vascular endothelial growth factor receptor correlate with the size of papillary thyroid carcinoma in children and young adults.
Fenton C; Patel A; Dinauer C; Robie DK; Tuttle RM; Francis GL
Thyroid; 2000 Apr; 10(4):349-57. PubMed ID: 10807064
[TBL] [Abstract][Full Text] [Related]
3. Correlation of E-cadherin, VEGF, COX-2 expression to prognostic parameters in papillary thyroid carcinoma.
Erdem H; Gündogdu C; Sipal S
Exp Mol Pathol; 2011 Jun; 90(3):312-7. PubMed ID: 21335003
[TBL] [Abstract][Full Text] [Related]
4. Influence of the BRAF V600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancer.
Jo YS; Li S; Song JH; Kwon KH; Lee JC; Rha SY; Lee HJ; Sul JY; Kweon GR; Ro HK; Kim JM; Shong M
J Clin Endocrinol Metab; 2006 Sep; 91(9):3667-70. PubMed ID: 16772349
[TBL] [Abstract][Full Text] [Related]
5. Increased expression of vascular endothelial growth factor C in papillary thyroid carcinoma correlates with cervical lymph node metastases.
Yu XM; Lo CY; Chan WF; Lam KY; Leung P; Luk JM
Clin Cancer Res; 2005 Nov; 11(22):8063-9. PubMed ID: 16299237
[TBL] [Abstract][Full Text] [Related]
6. Systemic administration of vascular endothelial growth factor monoclonal antibody reduces the growth of papillary thyroid carcinoma in a nude mouse model.
Bauer AJ; Patel A; Terrell R; Doniparthi K; Saji M; Ringel M; Tuttle RM; Francis GL
Ann Clin Lab Sci; 2003; 33(2):192-9. PubMed ID: 12817624
[TBL] [Abstract][Full Text] [Related]
7. [Pathologic study of expression and significance of matrix metalloproteinases-9, tissue inhibitor of metalloproteinase-1, vascular endothelial growth factor and transforming growth factor beta-1 in papillary carcinoma and follicular carcinoma of thyroid].
Wang T; Jiang CX; Li Y; Liu X
Zhonghua Bing Li Xue Za Zhi; 2009 Dec; 38(12):824-8. PubMed ID: 20193458
[TBL] [Abstract][Full Text] [Related]
8. Expression of Vascular Endothelial Growth Factor and Its Receptors in Thyroid Nodular Hyperplasia and Papillary Thyroid Carcinoma: A Tertiary Health Care Centre Based Study.
Mohamad Pakarul Razy NH; Wan Abdul Rahman WF; Win TT
Asian Pac J Cancer Prev; 2019 Jan; 20(1):277-282. PubMed ID: 30678450
[TBL] [Abstract][Full Text] [Related]
9. Vascular endothelial growth factor expression is higher in differentiated thyroid cancer than in normal or benign thyroid.
Soh EY; Duh QY; Sobhi SA; Young DM; Epstein HD; Wong MG; Garcia YK; Min YD; Grossman RF; Siperstein AE; Clark OH
J Clin Endocrinol Metab; 1997 Nov; 82(11):3741-7. PubMed ID: 9360534
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of RET/PTC expression in papillary thyroid carcinoma and its correlation with prognostic factors in a north Indian population.
Mishra A; Agrawal V; Krishnani N; Mishra SK
J Postgrad Med; 2009; 55(3):171-5. PubMed ID: 19884740
[TBL] [Abstract][Full Text] [Related]
11. Vascular endothelial growth factors and angiopoietins in presentations and prognosis of papillary thyroid carcinoma.
Hsueh C; Lin JD; Wu IC; Chao TC; Yu JS; Liou MJ; Yeh CJ
J Surg Oncol; 2011 Apr; 103(5):395-9. PubMed ID: 21400522
[TBL] [Abstract][Full Text] [Related]
12. HLA-G is differentially expressed in thyroid tissues.
de Figueiredo Feitosa NL; Crispim JC; Zanetti BR; Magalhães PK; Soares CP; Soares EG; Neder L; Donadi EA; Maciel LM
Thyroid; 2014 Mar; 24(3):585-92. PubMed ID: 24089994
[TBL] [Abstract][Full Text] [Related]
13. [Differential protein expressions in papillary thyroid carcinoma patients with or without Hashimoto's thyroiditis].
Lu HZ; Zhang N; Liu W; Zhu XY; Qi D; Wang Y; Liu XY; Li ZJ
Zhonghua Zhong Liu Za Zhi; 2020 Jun; 42(6):463-468. PubMed ID: 32575941
[No Abstract] [Full Text] [Related]
14. Neuropilin-2 expression in papillary thyroid carcinoma: correlation with VEGF-D expression, lymph node metastasis, and VEGF-D-induced aggressive cancer cell phenotype.
Yasuoka H; Kodama R; Hirokawa M; Takamura Y; Miyauchi A; Inagaki M; Sanke T; Nakamura Y
J Clin Endocrinol Metab; 2011 Nov; 96(11):E1857-61. PubMed ID: 21880798
[TBL] [Abstract][Full Text] [Related]
15. VEGF-C and COX-2 expression in papillary thyroid cancer.
Siironen P; Ristimäki A; Narko K; Nordling S; Louhimo J; Andersson S; Haapiainen R; Haglund C
Endocr Relat Cancer; 2006 Jun; 13(2):465-73. PubMed ID: 16728574
[TBL] [Abstract][Full Text] [Related]
16. [Expression and significance of VEGF, VEGF-C, and VEGF-D in papillary thyroid carcinoma].
Jiang HG; Gao M; Tang WP; Li FH; Cai QZ
Ai Zheng; 2005 Sep; 24(9):1136-9. PubMed ID: 16159441
[TBL] [Abstract][Full Text] [Related]
17. Encapsulated papillary thyroid carcinoma: a clinico-pathologic study of 106 cases with emphasis on its morphologic subtypes (histologic growth pattern).
Rivera M; Tuttle RM; Patel S; Shaha A; Shah JP; Ghossein RA
Thyroid; 2009 Feb; 19(2):119-27. PubMed ID: 19191744
[TBL] [Abstract][Full Text] [Related]
18. Increased expression of the vascular endothelial growth factor is a pejorative prognosis marker in papillary thyroid carcinoma.
Klein M; Vignaud JM; Hennequin V; Toussaint B; Bresler L; Plénat F; Leclère J; Duprez A; Weryha G
J Clin Endocrinol Metab; 2001 Feb; 86(2):656-8. PubMed ID: 11158026
[TBL] [Abstract][Full Text] [Related]
19. Clinical relevance of vascular endothelial growth factor for thyroid neoplasms.
Huang SM; Lee JC; Wu TJ; Chow NH
World J Surg; 2001 Mar; 25(3):302-6. PubMed ID: 11343180
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of infiltration and angiogenesis by thrombospondin-1 in papillary thyroid carcinoma.
Tanaka K; Sonoo H; Kurebayashi J; Nomura T; Ohkubo S; Yamamoto Y; Yamamoto S
Clin Cancer Res; 2002 May; 8(5):1125-31. PubMed ID: 12006528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]